关于 "津巴布韦开始使用基于多鲁曲韦的一线抗逆转录病毒疗法的患者的病毒学、体重和耐药性结果 "一文的关注和澄清。

{"title":"关于 \"津巴布韦开始使用基于多鲁曲韦的一线抗逆转录病毒疗法的患者的病毒学、体重和耐药性结果 \"一文的关注和澄清。","authors":"Oguz Karabay","doi":"10.1097/QAD.0000000000003885","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":7502,"journal":{"name":"AIDS","volume":null,"pages":null},"PeriodicalIF":3.4000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Concerns and clarifications regarding the article 'Virological, weight, and drug resistance outcomes among patients initiating a dolutegravir-based first line ART regimen in Zimbabwe'.\",\"authors\":\"Oguz Karabay\",\"doi\":\"10.1097/QAD.0000000000003885\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":7502,\"journal\":{\"name\":\"AIDS\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.4000,\"publicationDate\":\"2024-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"AIDS\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1097/QAD.0000000000003885\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/5/30 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"AIDS","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/QAD.0000000000003885","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/30 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}